Core Insights - Champions Oncology, Inc. (CSBR) is a significant entity in translational oncology research, providing R&D solutions to biopharmaceutical companies using patient-derived xenograft models [1] Financial Performance - On December 15, 2025, CSBR reported earnings per share (EPS) of $0.01, below the estimated $0.08, with actual revenue of $15 million, short of the estimated $16.42 million [2][6] - The oncology services segment achieved a profit of $7.8 million with a margin of 52%, indicating strong performance [3][6] - For the first half of fiscal 2026, total revenue rose by 5% to $29 million, with oncology services profit at $13.8 million and an adjusted EBITDA of $962,000 [4] Revenue Highlights - CSBR achieved record quarterly service revenue of $14.9 million in Q2 2026, marking an 11% increase in total revenue to $15 million [2][6] Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 44.63, indicating a high valuation relative to earnings, and a price-to-sales ratio of 2.50 [5]